Mackenzie Financial Corp Has $69.51 Million Holdings in Waters Corporation $WAT

Mackenzie Financial Corp raised its stake in Waters Corporation (NYSE:WAT) by 12.2% in the third quarter, Holdings Channel.com reports. The firm owned 231,852 shares of the medical instruments supplier’s stock after acquiring an additional 25,182 shares during the period. Mackenzie Financial Corp’s holdings in Waters were worth $69,512,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of WAT. Root Financial Partners LLC bought a new position in shares of Waters during the 3rd quarter worth about $26,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Waters in the third quarter valued at about $26,000. Hantz Financial Services Inc. lifted its stake in shares of Waters by 115.4% in the third quarter. Hantz Financial Services Inc. now owns 112 shares of the medical instruments supplier’s stock valued at $34,000 after buying an additional 60 shares during the period. CYBER HORNET ETFs LLC acquired a new stake in Waters during the second quarter worth about $53,000. Finally, Versant Capital Management Inc increased its stake in Waters by 510.3% during the third quarter. Versant Capital Management Inc now owns 177 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 148 shares during the period. 94.01% of the stock is currently owned by institutional investors and hedge funds.

Waters Stock Down 0.7%

NYSE WAT opened at $297.65 on Thursday. The company has a current ratio of 1.73, a quick ratio of 1.27 and a debt-to-equity ratio of 0.37. The stock’s 50 day moving average is $356.51 and its two-hundred day moving average is $351.37. The company has a market capitalization of $29.20 billion, a price-to-earnings ratio of 27.64, a PEG ratio of 2.06 and a beta of 1.20. Waters Corporation has a 1-year low of $275.05 and a 1-year high of $414.15.

Waters (NYSE:WAT) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $4.53 earnings per share for the quarter, beating the consensus estimate of $4.50 by $0.03. Waters had a return on equity of 34.79% and a net margin of 20.30%.The company had revenue of $932.36 million for the quarter, compared to analyst estimates of $928.17 million. During the same period in the prior year, the company posted $4.10 EPS. The company’s revenue was up 6.9% compared to the same quarter last year. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. Equities analysts forecast that Waters Corporation will post 12.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Wall Street Zen cut Waters from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Evercore initiated coverage on Waters in a report on Tuesday, February 10th. They set a “hold” rating and a $360.00 price objective on the stock. William Blair assumed coverage on Waters in a research note on Monday, January 5th. They issued an “outperform” rating for the company. Bank of America reduced their target price on Waters from $410.00 to $350.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Finally, Guggenheim reiterated a “buy” rating and set a $440.00 price target on shares of Waters in a research note on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Waters has a consensus rating of “Moderate Buy” and a consensus price target of $393.84.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.